[
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Thursday when compared to competitors",
    "summary": "Johnson & Johnson stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d94d3257a1e87d03d509670a1e52b2fa194b9cd725d92b5ef581913dab2e3b1d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731601860,
      "headline": "Johnson & Johnson stock underperforms Thursday when compared to competitors",
      "id": 131413909,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d94d3257a1e87d03d509670a1e52b2fa194b9cd725d92b5ef581913dab2e3b1d"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?",
    "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=02ed3de11d6a4991be722a9ac87ca663acb1154077a9a0a74c8cd831826d61c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731601815,
      "headline": "Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?",
      "id": 131359816,
      "image": "https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=02ed3de11d6a4991be722a9ac87ca663acb1154077a9a0a74c8cd831826d61c3"
    }
  },
  {
    "ts": null,
    "headline": "Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% following treatment with investigational nipocalimab in adult patients with moderate-to-severe Sjögren's disease (SjD). These data were included in a plenary session presentation (Abstract #2527) and two posters (Abstracts #1427 and #2294) and are among the Company's 43 oral and poster pr",
    "url": "https://finnhub.io/api/news?id=c6359b95f4d9b22a0ec5455ebdd863e542ddd910dce80868904fe8c6038abd89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731596400,
      "headline": "Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study",
      "id": 131359817,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% following treatment with investigational nipocalimab in adult patients with moderate-to-severe Sjögren's disease (SjD). These data were included in a plenary session presentation (Abstract #2527) and two posters (Abstracts #1427 and #2294) and are among the Company's 43 oral and poster pr",
      "url": "https://finnhub.io/api/news?id=c6359b95f4d9b22a0ec5455ebdd863e542ddd910dce80868904fe8c6038abd89"
    }
  },
  {
    "ts": null,
    "headline": "How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth",
    "summary": "The portfolio effectively integrates the generation of dividend income with the potential for dividend growth. Read more to see my recommendations.",
    "url": "https://finnhub.io/api/news?id=94fcbbc64adccf04fc7e7a2c5d06e3b17e13f5899c88184e20788ca30ad264c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731596400,
      "headline": "How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth",
      "id": 131356026,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226730172/image_1226730172.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The portfolio effectively integrates the generation of dividend income with the potential for dividend growth. Read more to see my recommendations.",
      "url": "https://finnhub.io/api/news?id=94fcbbc64adccf04fc7e7a2c5d06e3b17e13f5899c88184e20788ca30ad264c3"
    }
  },
  {
    "ts": null,
    "headline": "J&J: Phase 2 endpoint met in Sjögren's disease",
    "summary": "Johnson & Johnson announced on Thursday that a Phase 2 study had met its primary endpoint in the treatment of Sjögren's syndrome, an autoimmune disease characterized by dry mucous membranes.The...",
    "url": "https://finnhub.io/api/news?id=cc3aee939b1b40416eccee2642468add3715f5c3161a27fd309a918c25ed3cd5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731582193,
      "headline": "J&J: Phase 2 endpoint met in Sjögren's disease",
      "id": 131350851,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced on Thursday that a Phase 2 study had met its primary endpoint in the treatment of Sjögren's syndrome, an autoimmune disease characterized by dry mucous membranes.The...",
      "url": "https://finnhub.io/api/news?id=cc3aee939b1b40416eccee2642468add3715f5c3161a27fd309a918c25ed3cd5"
    }
  },
  {
    "ts": null,
    "headline": "J&J: distribution agreement with Responsive Arthroscopy",
    "summary": "J&J announces that its 'MedTech' division has reached an exclusive commercial distribution agreement in the USA with Responsive Arthroscopy, a company specializing in soft tissue repair solutions for...",
    "url": "https://finnhub.io/api/news?id=eac110e50ad4d2ab4effbb566e8b5815ddcb6ddaeffb6fff40a4420aa1171b81",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731577704,
      "headline": "J&J: distribution agreement with Responsive Arthroscopy",
      "id": 131349214,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "J&J announces that its 'MedTech' division has reached an exclusive commercial distribution agreement in the USA with Responsive Arthroscopy, a company specializing in soft tissue repair solutions for...",
      "url": "https://finnhub.io/api/news?id=eac110e50ad4d2ab4effbb566e8b5815ddcb6ddaeffb6fff40a4420aa1171b81"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions",
    "summary": "WEST CHESTER, Penn. - November 14, 2024 - Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced today an exclusive commercial distribution agreement in the...",
    "url": "https://finnhub.io/api/news?id=2cb89b8d20969abddc2112b670491b383b618dacc008d1532601eac28e054928",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731574391,
      "headline": "Johnson & Johnson : MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions",
      "id": 131348082,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "WEST CHESTER, Penn. - November 14, 2024 - Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced today an exclusive commercial distribution agreement in the...",
      "url": "https://finnhub.io/api/news?id=2cb89b8d20969abddc2112b670491b383b618dacc008d1532601eac28e054928"
    }
  }
]